(Total Views: 949)
Posted On: 07/24/2020 9:37:33 AM
Post# of 148919
Understanding REGN and CYDY
1. CYDY would be first to market if the PII tests come out well.
PIII should also be completed first. Thats kind of important.
2. US bought REGN supply. If RGEN beats CYDY by a bit, there will still be worldwide demand unable to currently be met.
3. REGN in EBOLA was the best, but really not great, the best of nothing great. So REGN is not the be all end all. I would not call it fantastic but you know, pretty good.
https://www.nejm.org/doi/full/10.1056/NEJMoa1910993
. At 28 days, death had occurred in 61 of 174 patients (35.1%) in the MAb114 group, as compared with 84 of 169 (49.7%) in the ZMapp group (P=0.007), and in 52 of 155 (33.5%) in the REGN-EB3 group, as compared with 79 of 154 (51.3%) in the ZMapp subgroup (P=0.002).
4. Even if REGN were later to surpass CYDY in covid in a " Cocktail "
there is no saying the adding Leronlimab would not enhance REGN.
No known contraindications it possibly would enhance presupposing pretty good results in the PII PIII
5. REGN has a reputation, money, and experience. CYDY not soo much.
But hey we were all once infants.
Nothing matters right now but the CYDY FDA PII results.
P.S. Nothing matters right now but the CYDY FDA PII results.
and before I go I will just mention, just in case I forgot to mention,
Nothing matters right now but the CYDY FDA PII results.
1. CYDY would be first to market if the PII tests come out well.
PIII should also be completed first. Thats kind of important.
2. US bought REGN supply. If RGEN beats CYDY by a bit, there will still be worldwide demand unable to currently be met.
3. REGN in EBOLA was the best, but really not great, the best of nothing great. So REGN is not the be all end all. I would not call it fantastic but you know, pretty good.
https://www.nejm.org/doi/full/10.1056/NEJMoa1910993
. At 28 days, death had occurred in 61 of 174 patients (35.1%) in the MAb114 group, as compared with 84 of 169 (49.7%) in the ZMapp group (P=0.007), and in 52 of 155 (33.5%) in the REGN-EB3 group, as compared with 79 of 154 (51.3%) in the ZMapp subgroup (P=0.002).
4. Even if REGN were later to surpass CYDY in covid in a " Cocktail "
there is no saying the adding Leronlimab would not enhance REGN.
No known contraindications it possibly would enhance presupposing pretty good results in the PII PIII
5. REGN has a reputation, money, and experience. CYDY not soo much.
But hey we were all once infants.
Nothing matters right now but the CYDY FDA PII results.
P.S. Nothing matters right now but the CYDY FDA PII results.
and before I go I will just mention, just in case I forgot to mention,
Nothing matters right now but the CYDY FDA PII results.
(7)
(0)Scroll down for more posts ▼
